Specifically, the increase in membranous EGFR under dasatinib treatment, which indirectly indicates the regaining of sensitization to cetuximab, strongly correlated (r > 0.8) with the increased tumor uptakes [145]. The gene discussed is EGFR; the disease is neoplasm.